PLAUR knockdown notably inhibited ccRCC cell proliferation and migration.<h4>Conclusion</h4>Our data suggested that CRRS may be employed as a reliable predictive biomarker that can provide therapeutic benefits for immunotherapy and targeted therapy in ccRCC. The gene discussed is PLAUR; the disease is nonpapillary renal cell carcinoma.